Hologic, Inc. (NASDAQ:HOLX) Shares Acquired by Prentiss Smith & Co. Inc.

Prentiss Smith & Co. Inc. grew its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 0.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 48,696 shares of the medical equipment provider’s stock after acquiring an additional 130 shares during the period. Hologic comprises approximately 2.5% of Prentiss Smith & Co. Inc.’s holdings, making the stock its 15th biggest position. Prentiss Smith & Co. Inc.’s holdings in Hologic were worth $3,967,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also modified their holdings of HOLX. Price T Rowe Associates Inc. MD grew its holdings in Hologic by 77.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,297,197 shares of the medical equipment provider’s stock worth $490,931,000 after buying an additional 2,753,016 shares in the last quarter. Swedbank AB acquired a new stake in Hologic during the 1st quarter worth about $120,827,000. Black Creek Investment Management Inc. lifted its stake in Hologic by 60.9% during the second quarter. Black Creek Investment Management Inc. now owns 2,338,970 shares of the medical equipment provider’s stock valued at $173,669,000 after buying an additional 885,524 shares in the last quarter. Mackenzie Financial Corp boosted its holdings in shares of Hologic by 1,023.3% in the second quarter. Mackenzie Financial Corp now owns 895,699 shares of the medical equipment provider’s stock worth $66,506,000 after buying an additional 815,960 shares during the period. Finally, Marshall Wace LLP acquired a new stake in shares of Hologic during the second quarter valued at approximately $39,427,000. Institutional investors own 94.73% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have weighed in on HOLX shares. Citigroup downgraded shares of Hologic from a “buy” rating to a “neutral” rating and cut their target price for the company from $95.00 to $85.00 in a research note on Tuesday, October 1st. Needham & Company LLC reaffirmed a “buy” rating and issued a $90.00 target price on shares of Hologic in a report on Tuesday, October 15th. JPMorgan Chase & Co. lifted their price target on shares of Hologic from $91.00 to $95.00 and gave the company an “overweight” rating in a report on Tuesday, July 30th. StockNews.com cut shares of Hologic from a “strong-buy” rating to a “buy” rating in a research note on Friday, September 27th. Finally, Stephens reissued an “overweight” rating and set a $92.00 price target on shares of Hologic in a research note on Tuesday, July 30th. Five investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, Hologic presently has a consensus rating of “Moderate Buy” and a consensus price target of $87.50.

Hologic Stock Down 1.0 %

Shares of Hologic stock traded down $0.85 during trading on Monday, reaching $80.72. The stock had a trading volume of 321,221 shares, compared to its average volume of 1,580,957. The company has a current ratio of 3.99, a quick ratio of 3.32 and a debt-to-equity ratio of 0.51. The company has a market capitalization of $18.84 billion, a price-to-earnings ratio of 41.62, a P/E/G ratio of 2.89 and a beta of 0.98. The stock has a fifty day moving average price of $80.94 and a two-hundred day moving average price of $77.74. Hologic, Inc. has a 52 week low of $64.02 and a 52 week high of $84.67.

Hologic (NASDAQ:HOLX) last released its earnings results on Monday, July 29th. The medical equipment provider reported $1.06 EPS for the quarter, beating the consensus estimate of $1.02 by $0.04. Hologic had a return on equity of 19.53% and a net margin of 17.59%. The firm had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $1 billion. The business’s quarterly revenue was up 2.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.93 EPS. Sell-side analysts predict that Hologic, Inc. will post 4.09 EPS for the current fiscal year.

Insider Activity at Hologic

In other news, insider Benjamin Jordan Cohn sold 5,093 shares of Hologic stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $81.99, for a total transaction of $417,575.07. Following the completion of the sale, the insider now owns 10,476 shares of the company’s stock, valued at approximately $858,927.24. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, insider Benjamin Jordan Cohn sold 5,093 shares of the firm’s stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $81.99, for a total transaction of $417,575.07. Following the transaction, the insider now directly owns 10,476 shares of the company’s stock, valued at approximately $858,927.24. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Brandon Schnittker sold 476 shares of the business’s stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $83.11, for a total transaction of $39,560.36. Following the transaction, the insider now owns 3,735 shares of the company’s stock, valued at approximately $310,415.85. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.75% of the stock is owned by company insiders.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.